A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Gastric cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-059
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Sep 2017 Results presented in a Merck & Co media release.
    • 22 Sep 2017 According to a Merck & Co media release, FDA has approved KEYTRUDA the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.The application was based on data from this trial.
    • 08 Sep 2017 According to a Merck AG Media Release, data from all three cohorts of the registrational, phase 2 KEYNOTE-059 trial will be presented at at ESMO 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top